Comparison of Transplant Outcomes for Low-Dose and Standard-Dose Tacrolimus in Kidney Transplant Recipients.
Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
Meeting: 2016 American Transplant Congress
Abstract number: B126
Keywords: FK506, Kidney transplantation, Rejection, Renal function
Session Information
Session Name: Poster Session B: Drug Minimization
Session Type: Poster Session
Date: Sunday, June 12, 2016
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Objectives: There are few studies that compare the effect of different dose of tacrolimus after kidney transplantation. We investigated transplant outcome of low-dose and standard-dose tacrolimus in the post-transplant period.
Methods: This study included 280 patients who underwent kidney transplantation between 2010 and 2014. All the patients received tacrolimus, mycophenolic acid, and steroid. Patients were divided into low-dose and standard-dose tacrolimus group (4-7 and 7-12ng/ml for 0-2 months, 3-6 and 6-10ng/ml for 3-6 months, 2-5 and 5-8ng/ml for 7-12 months, respectively) by tacrolimus trough level at each period. We compared estimated glomerular filtration rate (eGFR), biopsy-proven acute rejection (BPAR), opportunistic infection and graft survival.
Results: There was no difference in baseline characteristics between two groups, except higher percentage of delayed graft function in low-dose group than standard-dose group (78.9% vs 21.1%, P=0.02). Standard-dose group showed higher mean eGFR than low-dose group for 0-2 months (69.9±17.2 vs 63.8±19.2 ml/min/1.73m2, p=0.006), while eGFR was not different by tacrolimus dose thereafter. Patients with persistent standard-dose tacrolimus for 12-months revealed significantly higher eGFR than those with persistent low-dose tacrolimus (65.9±14.3 vs 58.2±19.0 ml/min/1.73m2, p=0.025). Incidence of BPAR was not different until 6 months, however, BPAR was significantly higher in low-dose group than standard-dose group (3.9 vs 0.0%, P=0.039) for 7-12months. During mean follow-up of 31.9±16.7 months, no significant differences of serious infections and graft survival were observed.
Conclusions: Standard-dose tacrolimus was associated with better graft function after kidney transplantation. Maintenance of proper tacrolimus level after 6 months could reduce acute rejection. However, dosing of tacrolimus did not have significant effect on graft survival in kidney transplants with tacrolimus-based triple therapy regimen.
CITATION INFORMATION: Cho J.-H, Kim K, Kim M, Do W, Yang Y, Yim T, Hwang I, Lee J.-H, Kwon E, Jung H.-Y, Choi J.-Y, Park S.-H, Kim Y.-L, Kim C.-D. Comparison of Transplant Outcomes for Low-Dose and Standard-Dose Tacrolimus in Kidney Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:
Cho J-H, Kim K, Kim M, Do W, Yang Y, Yim T, Hwang I, Lee J-H, Kwon E, Jung H-Y, Choi J-Y, Park S-H, Kim Y-L, Kim C-D. Comparison of Transplant Outcomes for Low-Dose and Standard-Dose Tacrolimus in Kidney Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-transplant-outcomes-for-low-dose-and-standard-dose-tacrolimus-in-kidney-transplant-recipients/. Accessed May 9, 2025.« Back to 2016 American Transplant Congress